文献速递产科母胎医学

宫颈成熟球囊用于胎膜早破引产后的羊膜腔内感染风险:系统综述与Meta分析

Risk of Intra-Amniotic Infection After Cervical Ripening Balloon for Prelabor Rupture of Membranes: A Systematic Review and Meta-analysis.
PubMed 文献 · Obstet Gynecol · 2026-07-09

总体合并分析显示两组感染 odds 相似(OR 1.46, 95%CI 0.90-2.37),但仅限随机对照试验(RCT)和低偏倚风险研究的分析提示球囊与感染风险升高相关。

要点

  • 总体分析中球囊与药物引产的羊膜腔内感染 odds 无显著差异。
  • 仅限RCT分析时球囊组感染风险显著升高(OR 1.84, 95%CI 1.03-3.28)。
  • 低偏倚风险研究中球囊组感染 odds 仍显著升高(OR 1.74, 95%CI 1.01-3.01)。

核心结论

  • 总体羊膜腔内感染 odds 在宫颈成熟球囊与药物引产之间相似。
  • 仅限RCT和低偏倚风险研究的分析提示球囊使用与羊膜腔内感染增加相关。

研究设计与样本

  • 1074例接受宫颈成熟球囊,1091例接受药物引产(缩宫素、前列腺素或其组合)。
  • 检索MEDLINE、EMBASE、Web of Science、Cochrane Library和ClinicalTrials.gov,研究分娩时间2002至2023年。

主要发现

  • 球囊组羊膜腔内感染合并加权率为9.4%(95%CI 5.9-13.6%),药物组为7.0%(95%CI 4.4-10.2%)。
  • 总体合并OR为1.46(95%CI 0.90-2.37;I2 45%)。
  • 仅限RCT分析:OR 1.84(95%CI 1.03-3.28;I2 0%)。
  • 队列研究分析:OR 1.25(95%CI 0.50-3.13;I2 68%)。
  • 球囊与前列腺素比较OR 1.27(95%CI 0.60-2.70;I2 54%),与缩宫素比较OR 1.66(95%CI 0.74-3.75;I2 22%)。

临床怎么用

  • PROM引产选择球囊或药物时,需权衡总体相似但RCT和低偏倚研究中球囊感染风险升高的信号。
  • 与前列腺素或缩宫素相比,球囊的感染 odds 无显著差异,但研究间异质性需注意。

局限性

  • 纳入研究异质性中等(总体I2 45%),队列研究异质性较高(I2 68%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the odds of intra-amniotic infection among individuals with prelabor rupture of membranes (PROM) who underwent labor induction with a cervical ripening balloon, compared with the odds of infection from a pharmacologic method, by performing a systematic review and meta-analysis. DATA SOURCES: MEDLINE through the PubMed interface, EMBASE, Web of Science, Cochrane Library, and ClinicalTrials.gov were searched for studies that evaluated intra-amniotic infection among individuals with PROM who were induced with a cervical ripening balloon compared with induction with oxytocin, prostaglandin, or some combination thereof. METHODS OF STUDY SELECTION: Two reviewers independently screened studies, extracted data, and assessed study quality. Odds ratios (OR) with 95% CIs were pooled using a randoms effect model. TABULATION, INTEGRATION, AND RESULTS: Fourteen studies, eight randomized controlled trials (RCTs), and six retrospective cohort studies, which included 2,165 participants, met inclusion criteria; 1,074 participants underwent the cervical ripening balloon and 1,091 received pharmacologic agents. Studies included deliveries that occurred in 2002 through 2023. Six studies were from the United States, three from France, two from Finland, and one each from Iran, the Netherlands, and Sweden. The pooled weighted rate of intra-amniotic infection was 9.4% (95% CI, 5.9-13.6%) with cervical ripening balloon and 7.0% (95% CI, 4.4-10.2%) with pharmacologic methods (OR 1.46; 95% CI, 0.90-2.37; I2 45%). In analyses restricted to RCTs, cervical ripening balloon was associated with increased intra-amniotic infection (OR 1.84; 95% CI, 1.03-3.28; I2 0%), whereas no association was observed in cohort studies (OR 1.25; 95% CI, 0.50-3.13; I2 68%). Rates of intra-amniotic infection were similar between cervical ripening balloon and prostaglandin (OR 1.27; 95% CI, 0.60-2.70; I2 54%) and were similar between cervical ripening balloon and oxytocin (OR 1.66; 95% CI, 0.74-3.75; I2 22%). Among studies assessed as a low risk of bias, cervical ripening balloon was associated with higher odds of intra-amniotic infection than pharmacologic methods (OR 1.74; 95% CI, 1.01-3.01; I2 30%). CONCLUSION: Overall intra-amniotic infection odds were similar between cervical ripening balloon and a pharmacologic induction among individuals with PROM. However, analysis limited to RCTs and low risk of bias studies suggests an association between cervical ripening balloon use and increased intra-amniotic infection. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD420251085355.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Hessami K, Tounsi S, Gandhi M, et al. Risk of Intra-Amniotic Infection After Cervical Ripening Balloon for Prelabor Rupture of Membranes: A Systematic Review and Meta-analysis. Obstet Gynecol. 2026. PMID: 42424638. doi:10.1097/AOG.0000000000006362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。